The­seus goes back to pre­clin­i­cal mode af­ter ax­ing lead tar­get­ed ther­a­py over tol­er­a­bil­i­ty con­cerns, shares plum­met

The­seus Phar­ma­ceu­ti­cals has run in­to dose-lim­it­ing tox­i­c­i­ties that’s forc­ing the com­pa­ny to aban­don its KIT in­hibitor, two months af­ter pre­sent­ing ini­tial da­ta on the pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.